1st-Line Trials Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule NCT01499121 Tom Baker Cancer Centre Cross Cancer Institute

First Page		Document Content
Date: 2014-08-01 14:55:56 Juravinski Cancer Centre Hamilton Health Sciences		1st-Line Trials Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule NCT01499121 Tom Baker Cancer Centre Cross Cancer Institute Add to Reading List Source URL: www.kidneycancercanada.ca Download Document from Source Website File Size: 52,88 KB Share Document on Facebook